Gsk (GSK) Total Non-Current Liabilities (2009 - 2026)
Gsk (GSK) posted Total Non-Current Liabilities of $31.6 billion for Q4 2025, little changed on a QoQ basis from $31.7 billion in Q4 2024, and little changed year-over-year from $31.7 billion in Q4 2024.
Gsk (GSK) has 10 years of Total Non-Current Liabilities data on file, last reported at $31.6 billion in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities changed 0.18% year-over-year to $31.6 billion; the TTM figure through Dec 2025 stood at $31.6 billion (changed 0.18% YoY), while the FY2025 annual figure was $31.6 billion, changed 0.18% from the prior year.
- Total Non-Current Liabilities steadied at $31.6 billion in Q4 2025, from $31.7 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $46.0 billion in Q4 2021 and bottomed at $31.2 billion in Q4 2023.
- A 5-year average of $34.5 billion and a median of $31.7 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 30.47% — and 2024, when it climbed 1.51%.
- Year by year, Total Non-Current Liabilities stood at $46.0 billion in 2021, then sank by 30.47% to $32.0 billion in 2022, then dropped by 2.33% to $31.2 billion in 2023, then advanced by 1.51% to $31.7 billion in 2024, then declined by 0.18% to $31.6 billion in 2025.
- The last three Total Non-Current Liabilities figures came in at $31.6 billion (Q4 2025), $31.7 billion (Q4 2024), and $31.2 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.03 Bn |
| Dec 31, 2025 | -31.62 Bn |
| Sep 30, 2025 | -32.73 Bn |
| Jun 30, 2025 | -32.72 Bn |
| Mar 31, 2025 | -33.02 Bn |
| Dec 31, 2024 | 31.68 Bn |
| Sep 30, 2024 | -30.06 Bn |
| Jun 30, 2024 | -30.23 Bn |
| Mar 31, 2024 | -32.27 Bn |
| Dec 31, 2023 | 31.21 Bn |
| Sep 30, 2023 | -32.75 Bn |
| Jun 30, 2023 | -31.53 Bn |
| Mar 31, 2023 | -32.32 Bn |
| Dec 31, 2022 | 31.95 Bn |
| Sep 30, 2022 | -36.12 Bn |
| Jun 30, 2022 | -35.98 Bn |
| Mar 31, 2022 | -17.64 Bn |
| Dec 31, 2021 | 45.96 Bn |
| Sep 30, 2021 | -47.59 Bn |
| Jun 30, 2021 | -47.59 Bn |
| Mar 31, 2021 | -50.74 Bn |
| Dec 31, 2020 | 49.48 Bn |
| Jun 30, 2020 | -50.39 Bn |
| Mar 31, 2020 | -49.93 Bn |
| Dec 31, 2019 | 47.94 Bn |
| Sep 30, 2019 | -48.92 Bn |
| Jun 30, 2019 | -44.87 Bn |
| Mar 31, 2019 | -44.96 Bn |
| Dec 31, 2018 | 41.05 Bn |
| Sep 30, 2018 | -47.56 Bn |
| Jun 30, 2018 | -49.61 Bn |
| Mar 31, 2018 | -35.67 Bn |
| Dec 31, 2017 | 34.95 Bn |
| Sep 30, 2017 | -34.70 Bn |
| Jun 30, 2017 | -31.97 Bn |
| Mar 31, 2017 | -43.21 Bn |
| Dec 31, 2016 | 43.66 Bn |
| Sep 30, 2016 | -48.18 Bn |
| Jun 30, 2016 | -50.69 Bn |
| Mar 31, 2016 | -48.76 Bn |
| Dec 31, 2015 | -47.27 Bn |
| Sep 30, 2015 | -48.12 Bn |
| Jun 30, 2015 | -45.57 Bn |
| Mar 31, 2015 | -46.72 Bn |
| Dec 31, 2014 | -35.52 Bn |
| Sep 30, 2014 | -32.23 Bn |
| Jun 30, 2014 | -33.25 Bn |
| Mar 31, 2014 | -34.10 Bn |
| Dec 31, 2013 | -33.35 Bn |
| Sep 30, 2013 | -33.29 Bn |
| Jun 30, 2013 | -34.27 Bn |
| Mar 31, 2013 | -36.17 Bn |
| Dec 31, 2012 | 704.98 Mn |
| Sep 30, 2012 | -30.76 Bn |
| Jun 30, 2012 | -30.53 Bn |
| Mar 31, 2012 | -26.26 Bn |
| Dec 31, 2011 | 675.77 Mn |
| Sep 30, 2011 | -32.33 Bn |
| Jun 30, 2011 | -31.02 Bn |
| Mar 31, 2011 | -31.35 Bn |
| Dec 31, 2010 | -31.11 Bn |
| Sep 30, 2010 | -32.24 Bn |
| Jun 30, 2010 | -32.10 Bn |
| Mar 31, 2010 | -32.74 Bn |
| Dec 31, 2009 | -32.67 Bn |
| Sep 30, 2009 | -33.95 Bn |
| Jun 30, 2009 | -29.26 Bn |
| Mar 31, 2009 | -30.16 Bn |